Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of LY3819469 for elevated lipoprotein(a)
NL-OMON60476Phase 2Completed
- Sponsor
- Eli Lilly and Company
- Start
- Feb 2023
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised trial in dyslipidemia and lipoprotein(a) hyperlipoproteinemia (Lp(a)) comparing LY3819469 with Placebo (2 arms). Primary endpoint: Percent change from baseline in time-averaged lipoprotein(a) over Days 60-180. Started Feb 2023; status: completed.
02
Drugs
lepodisiran
03
Conditions
dyslipidemialipoprotein(a) hyperlipoproteinemia (Lp(a))
Beyond the preview
Go deeper on NL-OMON60476.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60476.